Fundhost Selects SS&C to Power Fund Accounting & Registry Services
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced Fundhost Limited, a boutique fund services provider to investment managers in Australia, has selected SS&C to support its fund services operations. Fundhost provides responsible entity, trustee, fund administration, registry, compliance, operations and support services to boutique Australian and international fund managers. The platform has AUD $2 billion in assets under management.
Under the agreement, Fundhost will use SS&C's proprietary platform to streamline its unit registry and fund administration operations. As part of the transition, 10 Fundhost employees have joined SS&C's Sydney office to ensure continuity of service and a seamless onboarding process for Fundhost clients.
'We are delighted to partner with SS&C Technologies, a global leader in fund administration and registry services,' said Anne Monge, Fundhost founder and Joint-CEO.
Drew Wilson, Joint-CEO of Fundhost, added: 'We selected SS&C for their proven expertise across private markets, hedge funds, and active ETFs, as well as their global infrastructure. With access to SS&C's technology and operational resources, we're well-positioned to broaden our capabilities while maintaining the high level of service our clients rely on.'
The agreement expands SS&C's presence in Australia and reinforces its commitment to supporting the local investment management industry with flexible, scalable solutions.
'We're excited to welcome our new colleagues and to deepen our presence in the Australian market,' said Euan McLeod, Head of Transfer Agency, SS&C Global Investor & Distribution Solutions, Australia. 'As demand for business process outsourcing continues to accelerate, we remain committed to delivering market-leading services to fund managers, custodians, and responsible entities across Australia.'
About Fundhost
Fundhost is a leading integrated Responsible Entity offering responsible entity, trustee, accounting, administration, registry and via strategic relationship with HSBC, custody under one roof. A boutique itself, Fundhost has supported the development of some of Australia's most successful boutiques.
About SS&C
SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. More than 22,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology.
Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com .
Follow SS&C on X , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603007928/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Nuwellis Inc (NUWE) Q2 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Challenges
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Nuwellis Inc (NASDAQ:NUWE) successfully resolved a temporary backorder issue with their sterilization vendor, which had impacted revenue. The pediatrics business segment showed strong performance with a 23% increase in revenue compared to the previous year. The company is transitioning its manufacturing to KDI precision manufacturing, expected to result in operational efficiencies and cost savings. Nuwellis Inc (NASDAQ:NUWE) has increased reimbursement rates for outpatient heart failure treatment, which is expected to drive growth in this segment. The company remains debt-free and recently raised $5 million in capital, strengthening its financial position. Negative Points Total revenue for the second quarter was $1.7 million, a 21% decline year-over-year. Heart failure and critical care revenue declined by 53% and 35% respectively, due to the temporary backorder. Gross margin decreased to 55.5% from 67.2% in the previous year, impacted by lower production volumes. Operating loss increased to $2.9 million compared to $2.3 million in the same quarter last year. Net loss attributable to common shareholders was $12.6 million, significantly higher than the $7.7 million loss in the previous year. Q & A Highlights Warning! GuruFocus has detected 2 Warning Signs with NUWE. Q: You mentioned the issue with the vendor regarding sterilization, which accounts for around $400,000 in revenue. When was it resolved, and will there be any impact in the current third quarter? A: It was resolved in the first week of July, and we are no longer in backorder. We are now building finished goods inventory rapidly to prepare for the transfer to KDI manufacturing. The issue is behind us, and the sterilization provider is fully operational. The impact was primarily in heart failure and cardiac surgery, as we prioritized inventory for pediatrics. (John Herb, CEO) Q: As the business evolves, where do you see the largest opportunity: pediatrics, critical care, or heart failure? A: We see growth opportunities in all three areas. Pediatrics continues to grow as more children's hospitals adopt Aquadex. In cardiac surgery, clinicians are using Aquadex to efficiently manage fluid post-surgery. The fastest-growing area is likely heart failure due to the outpatient opportunity, supported by increased reimbursement from $413 to $1639 per day for treatments in hospital outpatient clinics. (John Herb, CEO) Q: Can you elaborate on the strategic decisions made this quarter, such as the termination of the reverse HF clinical trial? A: We terminated the reverse HF clinical trial to reallocate approximately $4 million towards higher-impact growth areas. This decision was not related to device performance or patient safety concerns. We are focusing on cardiac surgery, pediatrics, and outpatient heart failure, where we see significant growth potential. (John Herb, CEO) Q: How did the temporary product backorder affect financial results for the quarter? A: The backorder primarily impacted heart failure and critical care revenues, which declined by 53% and 35%, respectively. However, pediatric revenues increased by 23% compared to the second quarter of 2024. The gross margin was affected, dropping to 55.5% from 67.2% due to lower production volumes. (Rob Scott, CFO) Q: What are the company's priorities moving forward? A: Our priorities include progressing towards being cash flow positive, achieving commercial targets in pediatrics and cardiac surgery, enhancing outpatient engagement with heart failure programs, completing our manufacturing transition, and increasing clinical awareness of Aquadex's role in fluid management. We aim to expand access to Aquadex and build a portfolio for fluid management across various care settings. (John Herb, CEO) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Venus Concept Inc (VERO) Q2 2025 Earnings Call Highlights: Strategic Shifts Amidst Economic ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Venus Concept Inc (NASDAQ:VERO) achieved a 15% quarter-over-quarter growth in Q2 2025, driven by strong execution despite a challenging environment. The company reported a 20% growth in total systems and subscription revenue, indicating robust demand in these segments. Cash system sales in the US increased to 65% of total US system sales in Q2 2025, up from 58% last year, reflecting a strategic shift towards higher quality cash revenues. Venus Concept Inc (NASDAQ:VERO) announced a strategic transaction to sell its Venus hair business for $20 million, allowing the company to focus on its core medical aesthetics business. The company made significant progress in improving its balance sheet, including reducing total debt obligations and enhancing its financial condition. Negative Points Second quarter revenue declined 5% year-over-year, with an 18% decrease in international sales offsetting a 5% increase in US sales. Gross profit decreased by 20% to $9.4 million, primarily due to economic uncertainty and tighter lending practices impacting capital equipment sales. Gross margin fell to 60.1% from 71.5% in the previous year, affected by supply disruptions and an adverse sales mix. Operating expenses increased by 6% to $18.5 million, indicating challenges in cost containment despite efforts to streamline operations. The company reported a net loss attributable to stockholders of $11.7 million for Q2 2025, compared to a net loss of $20 million in the same period last year. Q & A Highlights Warning! GuruFocus has detected 9 Warning Signs with VERO. Q: Can you provide more details on the strategic decision to sell the Venus hair business? A: Rajeev da Silva, CEO: The sale of the Venus hair business to Meta Health Group for $20 million is a strategic move to focus on our core global medical aesthetics business. This transaction is expected to improve revenue growth, lower operating expenses, enhance cash flow, and accelerate our path to long-term profitability. Meta Health Group, with its expertise in the aesthetic medical field, is an ideal acquirer to maximize the potential of the Venus hair business. Q: How did the company perform financially in the second quarter of 2025? A: Dominic Della Pena, CFO: We reported total revenue of $15.7 million, a 5% decrease year over year. The decline was driven by an 18% decrease in international revenue, partially offset by a 5% increase in U.S. revenue. Gross profit decreased by 20% to $9.4 million, primarily due to economic uncertainties and supply disruptions. Our net loss was $11.7 million, an improvement from the $20 million loss in the same quarter last year. Q: What are the current challenges impacting the company's performance? A: Rajeev da Silva, CEO: The global capital equipment environment remains uncertain, affecting the timing and pace of new system adoption. Factors such as customer financing pressures, economic uncertainty, high interest rates, and proposed tariffs are impacting system adoption. Our international business is particularly exposed to these macroeconomic headwinds. Q: What steps is Venus Concept taking to improve its financial condition? A: Dominic Della Pena, CFO: We have made significant progress in improving our balance sheet by amending agreements with our primary lender, increasing financing capacity, and exchanging convertible notes for preferred stock. We also raised $3.9 million through equity capital markets transactions. These efforts are aimed at enhancing our financial profile and supporting strategic growth initiatives. Q: What is the company's outlook for the remainder of 2025? A: Dominic Della Pena, CFO: Due to ongoing evaluations with lenders and investors, and current market conditions, we are not providing full-year 2025 financial guidance. However, we remain focused on managing cash burn, cost management, and strategic investments to support long-term growth. We are also exploring strategic alternatives to maximize shareholder value. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Ideal Power Inc (IPWR) Q2 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...
Cash Burn from Operating and Investing Activities: $2.5 million in Q2 2025, up from $2.2 million in Q2 2024. Cash Equivalents: $11.1 million as of June 30, 2025. Operating Expenses: $3.1 million in Q2 2025, compared to $2.9 million in Q2 2024. Net Loss: $3 million in Q2 2025, compared to $2.7 million in Q2 2024. Revenue: Modest revenue recorded for Q2 2025 as customers evaluate technology. Shares Outstanding: 8,498,014 shares as of June 30, 2025. Fully Diluted Share Count: 10,439,399 shares as of June 30, 2025. Warning! GuruFocus has detected 4 Warning Signs with IPWR. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Ideal Power Inc (NASDAQ:IPWR) shipped updated solid-state circuit breaker prototypes to their first design win customer, incorporating additional capabilities requested by the customer. The company entered into a collaboration with a fourth global Tier 1 automotive supplier, indicating expanding interest in their B-TRAN technology. Ideal Power Inc (NASDAQ:IPWR) successfully completed third-party automotive pre-qualification and reliability testing of B-TRAN devices with zero failures. The company added a partnership with Kaimei Electronic Corp to distribute their products throughout Asia, tapping into the world's largest market for power electronics. Stellantis issued a purchase order for custom development and packaged devices targeting multiple EV applications, broadening collaboration with one of the world's largest automakers. Negative Points The company's cash burn from operating and investing activities increased to $2.5 million in Q2 2025, up from $2.2 million in Q2 2024. Ideal Power Inc (NASDAQ:IPWR) recorded a net loss of $3 million in Q2 2025, compared to $2.7 million in Q2 2024. The company expects third-quarter 2025 cash burn to increase to approximately $2.7 million to $2.9 million. Initial orders from large companies evaluating their products are expected to be small, with revenue ramping up only as customers progress through their design cycles. The stock price seems to be lagging behind the company's commercial progress, indicating potential underappreciation by the market. Q & A Highlights Q: How should we think about the opportunity with Stellantis, and could Ideal Power's technology be exposed to all 16 Stellantis brands? A: R. Daniel Brdar, President and CEO, explained that Stellantis aims for commonality across their brands and EV platforms, meaning Ideal Power's technology could be integrated into multiple recognizable brands. However, some brands like Maserati might opt for higher-cost solutions like silicon carbide. The opportunity spans a broad range of mid-size vehicles and new brands. Q: What is the estimated power semiconductor content in an EV, and how does Ideal Power's technology fit into this? A: Timothy Burns, CFO, stated that the total power semiconductor content in an EV is about $1,100, with the drivetrain inverter being the largest component. Ideal Power's B-TRAN technology could contribute significantly, especially in the drivetrain inverter, which could account for several hundred dollars of content. Q: How many design opportunities are currently in Ideal Power's sales pipeline, and what is the volume of these opportunities? A: R. Daniel Brdar noted that the automotive side is more discrete with fewer players, involving five global auto OEMs and five Tier 1 suppliers. On the industrial side, there are many more opportunities, ranging from large recognizable companies to mid-sized ones. The focus is on industrial applications for initial design wins. Q: What are the challenges to closing sales, and are there any technical challenges with Ideal Power's technology? A: R. Daniel Brdar mentioned that the primary challenge is the education process, as B-TRAN is a new technology. Engineers need to become familiar with it through hands-on experience and technical education. There haven't been significant technical challenges, but ongoing education is crucial. Q: When will Ideal Power achieve cash flow break-even, and what factors influence this timeline? A: Timothy Burns explained that achieving cash flow break-even depends on product and customer mix and the pace of adoption. It only takes a few key design wins to reach break-even, as a single design win can generate millions in annual revenue. The focus is on industrial markets for initial revenue. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
